Medindia

X

China Biopharma to Introduce an Immunotherapeutic Vaccine into China

by Medindia Content Team on  June 27, 2007 at 4:12 PM Drug News   - G J E 4
China Biopharma to Introduce an Immunotherapeutic Vaccine into China
China Biopharma, Inc., has reached a tentative agreement with Delmont Laboratory to introduce its immunotherapeutic vaccine Staphage Lysate that treats diseases of staphylococcal infection. According to this initial agreement, Delmont Laboratory will supply bulk materials and China Biopharma will contract local manufactures for the final packaging in China.
Advertisement

CBPC will also conduct a study before a definitive agreement is to be signed. This product requires a clinical study and an approval from the Chinese SFDA before it is sold in China, though the product already has the FDA approval.

Advertisement
As many as 1.2 million U.S. hospital patients may be infected each year with a Staph infection which is resistant to antibiotics, according to a research conducted by Association for Professional in Infection Control and Epidemiology.

Each year up to 119,000 of these patients may die from the tough-to-treat strain of bacterium, called methicillin-resistant Staphylococcus aureus (MRSA). No effective drugs are currently available in China to treat this infection and this vaccine is greatly needed.

The approval process may take about two years and once approved it would bring up to $20-30 million sales revenue every year.

Source: PR Newswire
LIN/M
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All